Sai Life Sciences Limited
Goldman Sachs decreased its stake in Sai Life Sciences Limited from 1.23% to 1.18%, selling 1,14,523 shares.
A contract research and manufacturing organization serving the pharmaceutical and biotechnology industries, Sai Life Sciences conducts research activities and produces customized solutions for clients globally. Incorporated in 1999, the company operates as a specialized service provider, offering integrated capabilities across drug development, formulation, and manufacturing to support its customers' product pipelines and commercial operations in India and international markets.
US-based global investment bank (USD 1.6 trillion in assets, USD 3 trillion+ in client AUM through Goldman Sachs Asset Management). India FPI activity covers proprietary, market-making, client flows and active asset management mandates in listed Indian equities.